Literature DB >> 29065779

Open surgery for iliofemoral deep vein thrombosis with temporary arteriovenous fistula remains valuable.

Markus U Wagenhäuser1,2, Hellai Sadat1, Philip Dueppers1, Yvonne K Meyer-Janiszewski1, Joshua M Spin2, Hubert Schelzig1, Mansur Duran1.   

Abstract

Objective We assessed outcomes of open surgical venous thrombectomy with temporary arteriovenous fistula, and the procedure's effect on health-related quality of life. Method We retrospectively analyzed 48 (26 at long-term) patient medical records. Mortality rates, patency, and risk of post-thrombotic syndrome were analyzed using Kaplan-Meier estimation. The association between risk factors/coagulation disorders and patency/post-thrombotic syndrome along with patient health-related quality of life at long-term was analyzed employing various statistical methods. Results Patient one-year survival rate was 93 ± 4% and primary one-year patency rate was 89 ± 5% (secondary one-year patency rate 97 ± 3%). Freedom from post-thrombotic syndrome after eight years was 80 ± 12% (post-thrombotic syndrome rate 20 ± 12%). Health-related quality of life was impaired vs. normative data in the physical and social subscales, and in the mental component score ( p < .05). Conclusions Open surgical venous thrombectomy appears safe compared with literature-reported outcomes in similar patients using alternative approaches. Iliofemoral deep vein thrombosis impairs physical, social, and mental health-related quality of life.

Entities:  

Keywords:  Deep vein thrombosis; duplex ultrasound; post-thrombotic syndrome; quality of life assessment; surgery

Mesh:

Year:  2017        PMID: 29065779     DOI: 10.1177/0268355517736437

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  1 in total

1.  Surgical thrombectomy for iliofemoral deep vein thrombosis: Patient outcomes at 8.5 years.

Authors:  Dominic Mühlberger; Martin Wenkel; Georg Papapostolou; Achim Mumme; Markus Stücker; Stefanie Reich-Schupke; Thomas Hummel
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.